OmniAb, Inc. (NASDAQ: OABI) will report financial results for the three months ended March 31, 2025 after the close of the U.S. financial markets on Thursday, May 8, 2025, and will hold a conference ...

A multi-institutional team developed a chimeric antigen receptor (CAR) T cell-based strategy for specifically targeting AML cells in patients who relapsed following other treatments. The team ...

BriaPro has filed US patent applications for this technology ...

Recent innovations include engineering CAR T-cells to overcome the immunosuppressive tumour microenvironment and enhancing ...

ZW327, a potential first-in-class ADC targeting Ly6E, an antigen overexpressed in numerous tumor ... High throughput quantitative molecular characterization of cytotoxic antibody-drug conjugates in ...

The effectiveness of monoclonal antibodies in specifically targeting certain antigens has led to the ... In studies involving animal models, ISB2001 successfully reduced multiple myeloma tumors ...

Moreover, the panelists emphasized that real-world evidence goes beyond clinical trial data. It involves continuous patient monitoring, proactive adverse effect management, and adapting protocols ...

Global Bispecific Trispecific Antibodies Market Size Will Surpass US$ 50 Billion By 2030 Says Kuick ResearchDelhi, April 04, 2025 (GLOBE NE ...

Epsilogen, the global leader in the development of immunoglobulin E (IgE) antibody therapeutics, today announces that it has completed the acquisition of TigaTx, Inc., a biotechnology company ...